Evidence map›Paper›PMID 35199994›Full record

ArticleAnalytical chemistry2022

Tunable Duplex Semiquantitative Detection of Nucleic Acids with a Visual Lateral Flow Immunoassay Readout.

Justin M Rosenbohm, Catherine M Klapperich, Mario Cabodi

Abstract read
In one paragraph

Article in Analytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Justin M RosenbohmDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0001-8682-5473
Catherine M KlapperichDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0001-6103-849X
Mario CabodiDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.

Funding

Development of a semi-quantitative ligation-based assay for Hepatitis BR21AI149040 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI CABODI, MARIO · 2020 to 2021
$454k
NIAID NIH HHS R21 AI149040
6 · The paper itself

Abstract

Quantitative nucleic acid amplification testing (NAAT) is a key enabling technology for infectious disease management, especially in instances where viral load informs therapeutic decisions. Inadequate access to quantitative NAATs remains a challenge to the successful deployment of antiretroviral therapy (ART) regimens for patients with chronic hepatitis B virus (CHB) in low resourced settings (LRS). Current field-deployable NAATs are generally qualitative (yes/no) rather than quantitative in nature, making them ill-suited for viral load monitoring programs for CHB patients. Here, we report the development of a proof-of-concept molecular diagnostic test, the semiquantitative ligation and amplification (SQLA) assay, which achieves semiquantitative detection of input target DNA at two independently tunable detection thresholds with a simple visual readout. The SQLA assay utilizes a duplex competitive thermophilic helicase-dependent amplification (tHDA) chemistry and can be performed in under 1 h.

Indexed as

Hepatitis B, ChronicHepatitis B virusImmunoassayNucleic Acid Amplification TechniquesNucleic AcidsHumansMolecular Diagnostic TechniquesNucleic Acids

Identifiers

PMID35199994
PMCPMC10017168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.